Patents by Inventor Johannes Jan Platteeuw
Johannes Jan Platteeuw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11975013Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.Type: GrantFiled: September 1, 2022Date of Patent: May 7, 2024Assignee: SHORLA PHARMA LTD.Inventors: Sharon Cunningham, Orlaith Ryan, Johannes Jan Platteeuw
-
Patent number: 11964055Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.Type: GrantFiled: October 18, 2021Date of Patent: April 23, 2024Assignee: ESTETRA SRLInventors: Séverine Francine Isabelle Jaspart, Johannes Jan Platteeuw, Denny Johan Marijn Van Den Heuvel
-
Patent number: 11957694Abstract: An orodispersible solid pharmaceutical dosage unit of estetrol is disclosed. The solid dosage unit is easy to manufacture and suited for sublingual, buccal or sublabial administration. The orodispersible solid pharmaceutical dosage unit can include at least 100 ?g of an estetrol component and pharmaceutically acceptable excipients. Methods of manufacturing the orodispersible solid pharmaceutical dosage unit are also disclosed.Type: GrantFiled: May 26, 2020Date of Patent: April 16, 2024Assignee: ESTETRA SRLInventors: Séverine Francine Isabelle Jaspart, Johannes Jan Platteeuw, Denny Johan Marijn Van Den Heuvel
-
Patent number: 11793760Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.Type: GrantFiled: May 12, 2023Date of Patent: October 24, 2023Assignee: ESTETRA SRLInventors: Séverine Francine Isabelle Jaspart, Johannes Jan Platteeuw, Denny Johan Marijn Van Den Heuvel
-
Publication number: 20230293442Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt.% of estetrol particles containing at least 80 wt.% of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt.% of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 µg of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 µm to 50 µm. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.Type: ApplicationFiled: May 12, 2023Publication date: September 21, 2023Applicant: ESTETRA SRLInventors: Séverine Francine Isabelle JASPART, Johannes Jan PLATTEEUW, Denny Johan Marijn VAN DEN HEUVEL
-
Publication number: 20230041156Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.Type: ApplicationFiled: August 29, 2022Publication date: February 9, 2023Inventors: Sharon CUNNINGHAM, Orlaith RYAN, Johannes Jan PLATTEEUW
-
Publication number: 20230017521Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.Type: ApplicationFiled: September 1, 2022Publication date: January 19, 2023Inventors: Sharon CUNNINGHAM, Orlaith RYAN, Johannes Jan PLATTEEUW
-
Publication number: 20220183975Abstract: The present invention relates to tablet dosage formulations of oleyl phosphocholine for oral administration and the processes for their preparation. Specifically, the present invention provides a process for preparing an oleyl phosphocholine containing granulate, said process comprising a blending step, a hot melt agglomeration step and a milling step. The present invention further provides a process for preparing a tablet comprising the oleyl phosphocholine containing granulate, said process comprising the step of preparing an OIPC containing granulate according to the invention, a blending step, a compression step, and optionally a coating step. The invention further provides any intermediate and/or en product resulting from these steps and processes.Type: ApplicationFiled: April 10, 2020Publication date: June 16, 2022Applicant: Oblita Therapeutics BVBAInventor: Johannes Jan Platteeuw
-
Publication number: 20220096385Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.Type: ApplicationFiled: October 18, 2021Publication date: March 31, 2022Applicant: ESTETRA SPRLInventors: Séverine Francine Isabelle JASPART, Johannes Jan PLATTEEUW, Denny Johan Marijn VAN DEN HEUVEL
-
Patent number: 11147771Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.Type: GrantFiled: June 17, 2016Date of Patent: October 19, 2021Assignee: ESTETRA SPRLInventors: Séverine Francine Isabelle Jaspart, Johannes Jan Platteeuw, Denny Johan Marijn Van Den Heuvel
-
Patent number: 10894014Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit containing at least 100 ?g of an estetrol component selected from estetrol, estetrol esters and combinations thereof; wherein the solid dosage unit can be obtained by a process that comprises: providing a loading liquid comprising organic solvent; estetrol component and optionally one or more other pharmaceutically acceptable ingredients; mixing 1 part by weight of the loading liquid with 0.5-20 parts by weight of carrier particles to produce wet particles; removing organic solvent from the wet particles to produce loaded particles; optionally mixing the loaded particles with one or more tabletting excipients; and forming the loaded particles or the mixture of the loaded particles and the one or more tabletting excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.Type: GrantFiled: June 17, 2016Date of Patent: January 19, 2021Assignee: ESTETRA SPRLInventors: Séverine Francine Isabelle Jaspart, Johannes Jan Platteeuw, Denny Johan Marijn Van Den Heuvel
-
Patent number: 10888518Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit containing at least 100 ?g of an estetrol component selected from estetrol, estetrol esters and combinations thereof; wherein the solid dosage unit can be obtained by a process comprising: ?providing an aqueous liquid comprising water, estetrol component and optionally one or more other pharmaceutically acceptable ingredients; ?mixing 1 part by weight of the aqueous liquid with 0.5-20 parts by weight of the carrier particles to produce wet particles; ?removing water from the wet particles to produce loaded particles; ?optionally mixing the loaded particles with one or more tabletting excipients; and ?forming the loaded particles or the mixture of loaded particles and the one or more tabletting excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.Type: GrantFiled: June 20, 2016Date of Patent: January 12, 2021Assignee: ESTETRA SPRLInventors: Séverine Francine Isabelle Jaspart, Johannes Jan Platteeuw, Denny Johan Marijn Van Den Heuvel
-
Patent number: 10844088Abstract: The present invention relates to a process for the preparation of estra-1,3,5(10)-trien-3, 15a, 16a, 17?-tetraol (estetr-01), via a silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10), 16-tetraene, wherein A is a protecting group and B is —Si(R2)3. The invention further relates to a process for the synthesis of 3-A-oxy-estra-1,3,5(10), 15-tetraen-17-one, in which A is a protecting group, via silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10),16-tetraene, and B is —Si(R2)3.Type: GrantFiled: February 7, 2017Date of Patent: November 24, 2020Assignee: ESTETRA SPRLInventors: Johannes Jan Platteeuw, Herman Jan Tijmen Coelingh Bennink, Franciscus Wilhelmus Petrus Damen, Michiel Christian Alexander Van Vliet
-
Publication number: 20200352959Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit comprising: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable excipients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process that comprises compressing a dry blend of estetrol particles and one or more pharmaceutically acceptable excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.Type: ApplicationFiled: May 26, 2020Publication date: November 12, 2020Applicant: ESTETRA SPRLInventors: Séverine Francine Isabelle JASPART, Johannes Jan PLATTEEUW, Denny Johan Marijn VAN DEN HEUVEL
-
Patent number: 10660903Abstract: An orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg is disclosed. The dosage unit comprises (a) 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and (b) 75-99.9 wt. % of one or more pharmaceutically acceptable excipients. The solid dosage unit comprises at least 100 ?g of the estetrol component and can be obtained by a process that comprises compressing a dry blend of estetrol particles and one or more pharmaceutically acceptable excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and suited for sublingual, buccal or sublabial administration.Type: GrantFiled: July 2, 2018Date of Patent: May 26, 2020Assignee: ESTETRA SPRLInventors: Séverine Francine Isabelle Jaspart, Johannes Jan Platteeuw, Denny Johan Marijn Van Den Heuvel
-
Patent number: 10525099Abstract: The present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg, said dosage unit consisting of: 1-100 wt. % of particles consisting of: 0.01-10 wt. % of a partus control substance selected from oxytocin, carbetocin, atosiban and combinations thereof; 5-70 wt. % of buffering agent; 20-94 wt. % of branched glucan; 0-70 wt. % of other pharmaceutically acceptable ingredients; 0-95 wt. % of one or more pharmaceutically acceptable excipients; the solid dosage unit comprising at least 5 ?g of the partus control substance and having a pH buffer range of 3.5-5.7. The solid dosage unit of the present invention is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration. Furthermore, the dosage unit does not need to be stored and distributed under temperature controlled conditions.Type: GrantFiled: September 29, 2015Date of Patent: January 7, 2020Assignee: OXYTONE BIOSCIENCE B.V.Inventors: Johannes Jan Platteeuw, Herman Jan Tijmen Coelingh Bennink
-
Publication number: 20190125759Abstract: An orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg is disclosed. The dosage unit comprises (a) 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and (b) 75-99.9 wt. % of one or more pharmaceutically acceptable excipients. The solid dosage unit comprises at least 100 ?g of the estetrol component and can be obtained by a process that comprises compressing a dry blend of estetrol particles and one or more pharmaceutically acceptable excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and suited for sublingual, buccal or sublabial administration.Type: ApplicationFiled: July 2, 2018Publication date: May 2, 2019Applicant: Mithra Pharmaceuticals S.A.Inventors: Séverine Francine Isabelle JASPART, Johannes Jan PLATTEEUW, Denny Johan Marijn VAN DEN HEUVEL
-
Patent number: 10179107Abstract: The present invention relates to a tablet having a weight of 30-200 mg and consisting of: 60-100 wt. % of granules consisting of: 50-90% by weight of the granules of dehydroepiandrosterone (DHEA); 6-35% by weight of the granules of microcrystalline cellulose; 0-20% by weight of the granules of one or more other pharmaceutically acceptable granule ingredients; and 0-40 wt. % of one or more other pharmaceutically acceptable tablet components. These tablets can suitably be used to orally administer DHEA in dosages of around 50 mg and are sufficiently small to be incorporated in, for instance, ordinary oral contraceptive blister packs.Type: GrantFiled: July 17, 2012Date of Patent: January 15, 2019Assignee: PANTARHEI BIOSCIENCE B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Johannes Jan Platteeuw
-
Patent number: 10172913Abstract: An orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg is disclosed. The dosage unit consists of: (a) 5-100 wt. % of coated particles comprising 50-99 wt. % of a core particle and 1-50 wt. % of a coating that envelops the core particle, said coating consisting of: 0.01-10 wt. % of a partus control substance selected from oxytocin, carbetocin, atosiban and combinations thereof; 5-50 wt. % of buffering agent; 15-80 wt. % of branched glucan; 0-78 wt. % of other pharmaceutically acceptable ingredients; and (b) 0-95 wt. % of one or more pharmaceutically acceptable excipients; the solid dosage unit comprising at least 20 ?g of the partus control substance and having a pH buffer range of 3.5-5.7.Type: GrantFiled: September 29, 2015Date of Patent: January 8, 2019Assignee: Oxytone Bioscience B.V.Inventors: Johannes Jan Platteeuw, Herman Jan Tijmen Coelingh Bennink
-
Publication number: 20180185271Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit containing at least 100 ?g of an estetrol component selected from estetrol, estetrol esters and combinations thereof; wherein the solid dosage unit can be obtained by a process that comprises: providing a loading liquid comprising organic solvent; estetrol component and optionally one or more other pharmaceutically acceptable ingredients; mixing 1 part by weight of the loading liquid with 0.5-20 parts by weight of carrier particles to produce wet particles; removing organic solvent from the wet particles to produce loaded particles; optionally mixing the loaded particles with one or more tabletting excipients; and forming the loaded particles or the mixture of the loaded particles and the one or more tabletting excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.Type: ApplicationFiled: June 17, 2016Publication date: July 5, 2018Applicant: Mithra Pharmaceuticals S.A.Inventors: Séverine Francine Isabelle JASPART, Johannes Jan PLATTEEUW, Denny Johan Marjin VAN DEN HEUVEL